Genmab A/S

Genmab A/S is a Danish international biotechnology company specializing in the discovery, creation, and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Headquartered in Copenhagen, Denmark, the company's mission is to improve the lives of patients through innovative antibody-based products, driven by its core purpose of "Antibody Science to Impact."

Genmab's portfolio includes eight approved antibodies utilized in various marketed products. Key offerings include EPKINLY/TEPKINLY (epcoritamab) for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma, and Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer. A significant product, DARZALEX (daratumumab), co-developed with Johnson & Johnson, is a standard of care for multiple myeloma. The company leverages proprietary technologies such as DuoBody, HexaBody, DuoHexaBody, and HexElect to develop next-generation therapeutic antibodies.

Under the leadership of President and CEO Jan Van de Winkel, Genmab has recently made strategic moves to strengthen its market position. Notable developments include the mid-2024 acquisition of ProfoundBio for $1.8 billion, which expanded its antibody-drug conjugate capabilities, and the planned acquisition of Merus N.V. for approximately $8 billion, announced in September 2025. In January 2026, Genmab partnered with Anthropic to integrate AI solutions into its research and development processes. The company also reported strong first-quarter DARZALEX sales near $4 billion in April 2026, underscoring its continued growth and focus on high-impact late-stage programs.